IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Over 20 years ago, it was first proposed that autoinflammation underpins a handful of rare monogenic disorders characterized by recurrent fever and systemic inflammation. The subsequent identification of novel, causative genes directly led to a better understanding of how the innate immune system is regulated under normal conditions, as well as its dysregulation associated with pathogenic mutations. Early on, IL-1 emerged as a central mediator for these diseases, based on data derived from patient cells, mutant mouse models and definitive clinical responses to IL-1 targeted therapy. Since that time, our understanding of the mechanisms of autoinflammation has expanded beyond IL-1 to additional innate immune processes. However, the number and complexity of IL-1-mediated autoinflammatory diseases has also multiplied to include additional monogenic syndromes with expanded genotypes and phenotypes, as well as more common polygenic disorders seen frequently by the practising clinician. In order to increase physician awareness and update rheumatologists who are likely to encounter these patients, this review discusses the general pathophysiological concepts of IL-1-mediated autoinflammation, the epidemiological and clinical features of specific diseases, diagnostic challenges and approaches, and current and future perspectives for therapy. In this Review, the authors summarize the pathophysiological mechanisms of IL-1-mediated autoinflammation. They describe the epidemiological and clinical features of autoinflammatory diseases, challenges associated with diagnostics and disease management, and current and future therapies for targeting the IL-1 pathway. IL-1α, IL-1β and IL-1RA are highly regulated inflammatory mediators involved in damage- and pathogen-associated molecular pattern (DAMPs and PAMPs), and cell death pathways. Patients with evidence of systemic inflammation without persistent infection or autoantibodies should raise suspicion of an IL-1-mediated autoinflammatory disorder. Rare monogenic and common polygenic diseases with neutrophilia and inflammation might respond to targeting the IL-1 pathway. Genetic testing confirms IL-1-driven autoinflammatory disorders, yet new disease phenotype–genotype correlations continue to be identified. IL-1-targeted therapies are highly effective and safe; new therapeutics focus on targets independent of IL-1 receptor binding, including NLRP3, caspases, IRAK4 and MK2. IL-1α, IL-1β and IL-1RA are highly regulated inflammatory mediators involved in damage- and pathogen-associated molecular pattern (DAMPs and PAMPs), and cell death pathways. Patients with evidence of systemic inflammation without persistent infection or autoantibodies should raise suspicion of an IL-1-mediated autoinflammatory disorder. Rare monogenic and common polygenic diseases with neutrophilia and inflammation might respond to targeting the IL-1 pathway. Genetic testing confirms IL-1-driven autoinflammatory disorders, yet new disease phenotype–genotype correlations continue to be identified. IL-1-targeted therapies are highly effective and safe; new therapeutics focus on targets independent of IL-1 receptor binding, including NLRP3, caspases, IRAK4 and MK2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Martinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066
Gout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
Targeting the NLRP3 inflammasome in inflammatory diseases
Mangan, M. S. J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., & Latz, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.97 · Cited by 1,885
INTERLEUKIN-1 RECEPTOR ANTAGONIST: Role in Biology
Arend, W. P., Malyak, M., Guthridge, C. J., & Gabay, C. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.27 · Cited by 1,071
Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity
Mantovani, A., Dinarello, C. A., Molgora, M., & Garlanda, C. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.012 · Cited by 1,046
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810787 · Cited by 869
Bulua, A. C., Simon, A., Maddipati, R., Pelletier, M., Park, H., Kim, K.-Y., Sack, M. N., Kastner, D. L., & Siegel, R. M. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20102049 · Cited by 860
Hoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., Weinstein, S. P., Belomestnov, P., Yancopoulos, G. D., Stahl, N., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23687 · Cited by 577
Self-citation
Cited by
Pro-Inflammatory and Anti-Inflammatory Interleukins in Infectious Diseases: A Comprehensive Review
Al-Qahtani, A. A., Alhamlan, F. S., & Al-Qahtani, A. A. (2024) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed9010013 · Cited by 291
Gander-Bui, H. T. T., Schläfli, J., Baumgartner, J., Walthert, S., Genitsch, V., van Geest, G., Galván, J. A., Cardozo, C., Graham Martinez, C., Grans, M., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.023 · Cited by 47
Metadata
- Authors
- Broderick, L., & Hoffman, H. M.
- Venue
- Nature Reviews Rheumatology
- Published
- 2022-06-21
- Volume
- 18
- Issue
- 8
- Pages
- 448-463
- ISSN
- 1759-4790 (ISSN-L)
- 1759-4804
- OpenAlex
- W4283271499
- Cited by
- 171
- References
- 14
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting. https://app.cochat.ai/papers/10.1038/s41584-022-00797-1
- The paper
- Broderick, L., & Hoffman, H. M. (2022). IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting. Nature Reviews Rheumatology. https://doi.org/10.1038/s41584-022-00797-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.